VeloSano supports projects that will build upon and transition recent advancements in cancer research into new diagnostics and therapeutics with a high likelihood of leading to successful, future, extramural grant funding.

In our first three years, VeloSano has generated over $8 million dollars which has been used to finance 68 cancer research projects to bridge the funding gap for researchers and physicians at Cleveland Clinic. The following pages show a snapshot of the project types supported to date.
Number of Projects Funded

CANCER TYPE

- Colon Cancer: 9
- Leukemia: 8
- Breast Cancer: 4
- Lymphoma: 4
- Ovarian Cancer: 4
- Prostate Cancer: 4
- Lung Cancer: 3
- Bone Marrow Cancer: 3
- Pediatric / Young Adult: 3
- Kidney Cancer: 1
- Skin Cancer: 1
- Oral Cancer: 1
- Carcinoma: 1
- General: 21

VeloSano Funded Research | 2015 – 2017
Project Types
To read more specifically about each project and how the dollars raised have gone towards research, simply click on the icons or cancer type.
Project Types

DESCRIPTIONS

To learn more specifically on the projects funded for each cancer type, simply click on the information icon.

**BONE MARROW CANCER**
Spanning across Clinical Trials, Immunotherapy and Genomics, projects funded include the prevention and treatment of age-related myeloid neoplasia, development of a vaccine for multiple myeloma and targeting macrophage migration inhibitory factor to treat multiple myeloma. Research award recipients represent Cleveland Clinic’s Lerner Research Institute and Taussig Cancer Institute.

**BRAIN CANCER**
Immunotherapy and Genomics-related projects have been supported, including but not limited to enhancing the cell response in glioblastoma, novel treatment options for glioblastoma and a brain metastases research program (cancer cells that have spread to the brain from primary tumors in other organs of the body). Research award recipients represent Cleveland Clinic’s Lerner Research Institute and Neurological Institute.

**BREAST CANCER**
Projects funded encompass Clinical Trials (minimally toxic approach to breast cancer metastases and triple-negative breast cancer) and Genomics (HER-2 positive breast cancer). Research award recipients represent Cleveland Clinic’s Dermatology Institute, Digestive Diseases and Surgery Institute, Lerner Research Institute and Taussig Cancer Institute.

**CARCINOMA**
This Genomics project targeted lipid metabolism to prevent hepatocellular carcinoma progression. Research award recipients represent Cleveland Clinic’s Lerner Research Institute and Digestive Diseases and Surgery Institute.

**COLON CANCER**
From evaluating inhibitors of colon tumor progression, to a novel target for rectal cancer radiation sensitivity, to a colon cancer metastases program, these projects include Clinical Trials, Genomics and Immunotherapy. Research award recipients represent Cleveland Clinic’s Digestive Diseases and Surgery Institute, Genomic Medicine Institute, Lerner Research Institute and Taussig Cancer Institute.

**KIDNEY CANCER**
A Clinic Trial testing the safety and effectiveness of harnessing the patient’s immune system using checkpoint inhibitors to kill cancer cells in those with a certain type of kidney cancer called renal cell carcinoma. Research award recipient represents Cleveland Clinic’s Taussig Cancer Institute.

**LEUKEMIA**
From evaluating inhibitors of colon tumor progression, to a novel target for rectal cancer radiation sensitivity, to a chronic myelomonocytic leukemia program, these projects include Clinic Trials, Genomics and Immunotherapy. Research award recipients represent Cleveland Clinic’s Lerner Research Institute and Taussig Cancer Institute.

**LUNG CANCER**
Includes a Genomics project focused on predicting early resistance to targeted therapy, as well as an Immunotherapy project looking at the mechanisms of acquired chemo resistance in small cell lung cancer. Research award recipients represent Cleveland Clinic’s Taussig Cancer Institute.

**LYMPHOMA**
Genomics and Immunotherapy related projects covering large B cell lymphoma and relapsed lymphoid malignancies. Research award recipients represent Cleveland Clinic’s Lerner Research Institute.
ORAL CANCER
Focused on profiling the Mycobiome-Microbiome (bacteria that live in and around the body) in oral wash and normal-tumor pairs of oral cavity squamous cell carcinomas. Research award recipient represents Cleveland Clinic’s Lerner Research Institute.

OVARIAN CANCER
Projects include preserving women’s fertility through ovarian tissue freezing, as well as the identification of biomarkers of disease and drug targets for treatment of chemo-resistant ovarian cancer. Research award recipients represent Cleveland Clinic’s Glickman Urological and Kidney Institute, Lerner Research Institute and Taussig Cancer Institute.

PEDIATRIC / YOUNG ADULT
From a Genomics project for exome sequencing in youth / young adult patients with malignancies to Immunotherapy projects related to pediatric high grade glioma (brain cancer) and therapeutic responses in Hodgkin Lymphoma patients, pediatric cancer research projects are an important focus for VeloSano funding. Research award recipients represent Cleveland Clinic Children’s, Lerner Research Institute and Neurological Institute.

PROSTATE CANCER
Areas of focus range from identifying the mechanisms that drive therapy resistance to targeting HDL metabolism to prevent progression to lethal prostate cancer. Research award recipients represent Cleveland Clinic’s Glickman Urological and Kidney Institute, Lerner Research Institute and Taussig Cancer Institute.

SKIN CANCER
The generous funds provided by VeloSano support the Taussig Cancer Institute’s Center for Melanoma (C4M). Specifically, the funds will support investigation of how cells that inhibit the immune system called T regulatory cells and Myeloid Derived Suppressor Cells can be manipulated. In addition, laboratory and clinical studies will evaluate the tumor microenvironment and how to manipulate it to enhance immune therapies. The C4M is committed to rapid implementation of clinical trials testing the safety and efficacy of novel cancer immunotherapeutics in cutting edge clinical trials.

GENERAL
Many projects that have been funded by VeloSano dollars are those that can be applied across multiple cancer types. Examples include the management and prevention of cancer-associated thrombosis (blood clots resulting from cancer), graft versus host disease, using small molecules to prevent cancer cell growth, and new strategies for the preferential killing of cancer stem cells. Research award recipients represent Cleveland Clinic’s Genomic Medicine Institute, Lerner Research Institute and Taussig Cancer Institute.
Project Descriptions

**BONE MARROW CANCER**

**PILOT | 2015**  
**Jaroslaw Maciejewski, M.D., Ph.D.**  
Chairman, Staff, Translational Hematologic and Oncologic Research; Taussig Cancer Institute  
**Use of Metformin to Prevent and Treat Aging-Related Myeloid Neoplasia**  
Co-Investigators | Daniel J. Linder, M.D., Ph.D., Associate Medical Director, Translational Hematology and Oncology Research Taussig Cancer Institute | Tomas Radirovych, Ph.D., Associate Staff, Quantitative Health Sciences Lerner Research Institute

**PILOT | 2015**  
**Jianfei Qian, Ph.D.**  
Project Scientist, Cancer Biology; Lerner Research Institute  
**Developing a DKK1-DC Vaccine for Immunotherapy of Multiple Myeloma**

**PILOT | 2016**  
**Qing Yi, M.D., Ph.D.**  
Department of Cancer Biology; Lerner Research Institute  
**Targeting Macrophage Migration Inhibitory Factor (MIF) to Treat Multiple Myeloma**

**BRAIN CANCER**

**CCC | 2016**  
**Jill Barnholtz-Sloan, Ph.D.**  
Case Comprehensive Cancer Center  
**Hematologic Biomarkers of Treatment Response and Recurrence in Patients with Glioblastoma**

**PILOT | 2014**  
**Justin Durla Lathia, PhD**  
Cellular and Molecular Medicine; Lerner Research Institute  
**Reversing Immune Cell Suppression and Enhancing Cytotoxic T Cell Response in Glioblastoma by Targeting Myeloid-Derived Suppressor Cells**  
Co-PI | Michael Vogelbaum, M.D., Ph.D., Brain Tumor and Neuro-Oncology Center

**PILOT | 2014**  
**Jeremy N. Rich, M.D., MHSc**  
Brain Tumor and Neuro-Oncology Center; Lerner Research Institute  
**Acquired Epigenetic Changes as Therapeutic Targets in Glioblastoma Stem Cells**

**PILOT | 2015**  
**Steven Rosenfeld, M.D., Ph.D.**  
Senior Staff, Department of Cancer Biology and Burkhardt Brain Tumor Center; Neurological Institute  
**Enhancing the Efficacy of Kif11 Inhibitors for the Treatment of Glioblastoma**

**IMPACT | 2016**  
**Manmeet Ahluwalia, M.D.**  
Brain Tumor and Neuro-Oncology Center Hematology and Oncology; Neurological Institute  
**Brain Metastases Research Program**

**BREAST CANCER**

**PILOT | 2015**  
**Edward Maytin, M.D.**  
Staff, Biomedical Engineering; Lerner Research Institute, Dermatology  
**Minimally Toxic Approach to Breast Cancer Metastases: Capecitabine-Enhanced Photodynamic Therapy**  
Co-Investigator | Sanjay Anand, Ph.D., Project Staff, Biomedical Engineering Lerner Research Institute

**PILOT | 2015**  
**Alberto Montero, M.D.**  
Staff Physician / Associate Professor, Hematology Oncology; Taussig Cancer Institute  
**Targeting the Achilles’ Shield of Triple-Negative Breast Cancer by Androgen Blockade**  
Co-Investigators | Jame Abraham, M.D., Director, Breast Oncology Program Taussig Cancer Institute | Mohamed Abazeed, M.D., Ph.D., Associate Staff, Translational Hematology and Oncology Research Taussig Cancer Institute | Benjamin Calhoun, M.D., Ph.D., Director, Breast Pathology Anatomic Pathology

**PILOT | 2016**  
**Stephen Grobmyer, M.D.**  
Breast Services; Digestive Diseases and Surgery Institute  
**The Microbiome and Neoadjuvant Therapy in HER-2 Positive Breast Cancer**  
Co-Investigators | Jame Abraham, M.D., Taussig Cancer Institute | Benjamin Calhoun, M.D., Ph.D., Pathology and Laboratory Medicine Institute | Charles Sturgis, M.D., Pathology and Laboratory Medicine Institute | Zahraa AhHiili, M.D., Digestive Diseases and Surgery Institute

**CCC | 2016**  
**Youwei Zhang, Ph.D.**  
Case Comprehensive Cancer Center  
**Roles of UbcH7 in Tumorigenesis and Therapy Response**  
Co-Investigators | Ruth Keri, Nathan Berger, Ming Li
Project Descriptions

**CARCINOMA**

**PILOT | 2015**  
**J. Mark Brown, Ph.D.**  
Assistant Staff, Cellular and Molecular Medicine; Lerner Research Institute  
**Targeting Lipid Metabolism to Prevent Hepatocellular Carcinoma Progression**  
Co-Investigator | Federico Aucejo, M.D. Staff, General Surgery and Transplantation Digestive Disease Institute

**IMPACT | 2015**  
**J. Mark Brown, Ph.D.**  
Assistant Staff, Cellular and Molecular Medicine; Lerner Research Institute  
**Targeting Lipid Metabolism to Prevent Hepatocellular Carcinoma Progression**

**COLON CANCER**

**PILOT | 2015**  
**Paul Fox, M.D.**  
Cellular and Molecular Medicine; Lerner Research Institute  
**Evaluation of New Inhibitor of Blood Vessel Formation and Colon Tumor Progression**

**IMPACT | 2015**  
**Bin Zhang, Ph.D.**  
Assistant Staff; Genomic Medicine Institute  
**Novel Roles of LMAN1 Mutations in Colorectal Cancer Development**

**IMPACT | 2016**  
**Emina Huang, M.D.**  
Colorectal Surgery; Lerner Research Institute  
**Colon Cancer Metastasis**  
Co-PI | Xiaoxia Li, Ph.D. Staff, Lerner Research Institute

**PILOT | 2016**  
**Emina Huang, M.D.**  
Stem Cell Biology/Regenerative Medicine; LRI and Digestive Disease and Surgery Institute (DDSI)  
**Epigenetic Histone Modifications Track the Pathogenesis of Colitis Associated Cancer in Primary Human Organoids**

**IMPACT | 2016**  
**Matthew F. Kalady, M.D.**  
Department of Colorectal Surgery; Department of Stem Cell and Regenerative Medicine; Digestive Disease and Surgery Institute; Lerner Research Institute; Taussig Cancer Institute  
**Coenzyme A Synthase: A Novel Target for Rectal Cancer Radiation Sensitivity**

**IMPACT | 2016**  
**Xiaoxia Li, Ph.D.**  
Immunology; Lerner Research Institute  
**Colon Cancer Metastasis**

**CCCC | 2015**  
**Zhenghe Wang, Ph.D.**  
Case Comprehensive Cancer Center  
**Develop HTS Assay for Screening GPT2 Inhibitors to Target p13KCA-Mutated Colorectal Cancers**

**CCCC | 2016**  
**Zhenghe Wang, Ph.D.**  
Case Comprehensive Cancer Center  
**Develop GPT2 Inhibitors to Target P13KCA-Mutated Colorectal Cancers**  
Co-PI | Drew Adams

**CCCC | 2016**  
**Lan Zhou, M.D., Ph.D.**  
Case Comprehensive Cancer Center  
**HES1-loss Mediates Immune-Suppressive Microenvironment in Serrated Pathway of Colon Carcinogenesis**
Project Descriptions

**KIDNEY CANCER**

**PILOT | 2015**  
Brian Rini, M.D.  
Professor of Medicine, LRI; Leader, GU Program; Department of Hematology and Oncology; Taussig Cancer Institute

**Exploration of CD8+ T cell Infiltration and Other Immune Microenvironment Parameters in Primary Renal Cell Carcinoma Tumors as Biomarkers of Response to Checkpoint Inhibitor Therapy**  
Co-Investigators | James Finke, Ph.D., Staff, Department of Immunology Lerner Research Institute | Christopher Przybycin, M.D., Staff Pathologist Anatomic Pathology and Urology

**LEUKEMIA**

**PILOT | 2014**  
Sudipto Mukherjee, M.D., MPH  
Hematology and Oncology; Taussig Cancer Institute

**Genetic Determinants of Predisposition to Subsequent Myeloid Malignancies Induced by Cancer Therapy**

**PILOT | 2014**  
Yogen Saunthararajah, M.D.  
Hematology and Oncology; Taussig Cancer Institute

**Au Nano-Linker to Minimize the Side Effects of Standard AML Drugs**  
Co-PI | Shunji Egusa, Ph.D.

**PILOT | 2015**  
Xiaorong Gu, Ph.D.  
Project Staff, Translational Hematology and Oncology Research; Taussig Cancer Institute

**Novel, Precision Therapy for Relapsed NPM1-Mutated AML**

**Co-Investigator | Yogen Saunthararajah, M.D., Staff, Hematology and Oncology, Taussig Cancer Institute**

**PILOT | 2015**  
Kwok Peng Ng, Ph.D.  
Project Staff, Translational Hematology and Oncology Research; Taussig Cancer Institute

**Non-Cytotoxic Probes to Renew AML Differentiation and Spare Normal Stem Cells**

**Co-Investigators | Yogen Saunthararajah, M.D., Staff, Hematology and Oncology, Taussig Cancer Institute | Drew Adams, Ph.D., Assistant Professor, Genetics and Genome Sciences, Case Western Reserve University School of Medicine**

**IMPACT | 2015**  
Jaroslaw Maciejewski, M.D., Ph.D.  
Staff Physician; Translational Hematology and Oncology Research

**Chronic Myelomonocytic Leukemia**

**IMPACT | 2016**  
Jaroslaw Maciejewski, M.D., Ph.D.  
Translational Hematology and Oncology Research; Taussig Cancer Institute

**Chronic Myelomonocytic Leukemia**

**PILOT | 2015**  
Babal Kant Jha, Ph.D.  
Project Staff, Cancer Biology; Lerner Research Institute

**Developing a Potent Pharmacologic Inhibitor of Sonic Hedgehog Transcription Factor Glioma-Associated Protein (GLI) for the Treatment of Drug Resistant Myeloid Leukemia**

**Co-Investigator | James Phillips, Ph.D., Project Staff, Translational Hematology and Oncology Research, Taussig Cancer Institute**

**PILOT | 2016**  
Candece L. Gladson, M.D.  
Department of Cancer Biology; Lerner Research Institute

**Increased Macropinocytosis by Tumor-Associated Endothelial Cells Requires Integrin α3β1/CD151 and Promotes Angiogenesis**

**Co-Investigator | Cathleen Carlin, Ph.D., Professor, Department of Molecular Biology and Microbiology, Case Western Reserve University**

**Collaborator | Martin E. Hemler, Ph.D., Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute**
Project Descriptions

**LUNG CANCER**

**PILOT | 2014**

*Vamsidhar Velcheti, M.D.*
Hematology and Oncology; Taussig Cancer Institute

Genomic Correlation of Computer Aided Radiographic and Histomorphometric Feature Extraction Based Models in Lung Cancer and Novel Approach to Predicting Early Resistance to Targeted Therapy

**PILOT | 2015**

*Craig Peacock, Ph.D.*
Project Staff Scientist, Quality Officer; Taussig Cancer Institute

Mechanisms of Acquired Chemoresistence in Small Cell Lung Cancer

Co-Investigator | Mohamed Abazeed, M.D., Ph.D., Associate Staff, Translational Hematology and Oncology Research, Taussig Cancer Institute

**CCC | 2016**

*Junran Zhang, M.D., Ph.D.*
Case Comprehensive Cancer Center

Novel Approaches for Targeting PPP2R2A-defective Cancer Cells by ATR and CHK1 Inhibitor

**LYMPHOMA**

**PILOT | 2016**

*Neetu Gupta, Ph.D.*
Department of Immunology; Lerner Research Institute

Molecular Basis of Relapse in Diffuse Large B Cell Lymphoma

Co-Investigators | Brian Hill, M.D., Ph.D., Department of Hematology and Medical Oncology, Taussig Cancer Institute | Eric Hsi, M.D., Department of Clinical Pathology, Pathology and Laboratory Medicine, Institute

**PILOT | 2014**

*Neetu Gupta, Ph.D.*
Immunology; Lerner Research Institute

Targeting B Cell Lymphomas through Mechanistic Drug Design and Medicinal Chemistry

Co-PI | Brian T. Hill, M.D., Ph.D., Department of Hematology and Oncology, TCi
Co-Investigator | Angela H. Ting Ph.D., Genomic Medicine Institute, LRI

**ORAL CANCER**

**PILOT | 2016**

*Charis Eng, M.D., Ph.D.*
Genomic Medicine Institute; Lerner Research Institute

Mycobiome-Microbiome Profiling in Oral Wash and Normal-Tumor Pairs of Oral Cavity Squamous Cell Carcinomas

Co-PIs | Brian Burkey, M.D., M Ed, Head and Neck Oncology, Head and Neck Institute | Mahmoud Ghannoum, Ph.D., EMBA, Center for Medical Mycology, Department of Dermatology, Case Western Reserve, University School of Medicine

---

**LUNG CANCER • LYMPHOMA • ORAL CANCER**
Project Descriptions

OVARIAN CANCER

IMPACT | 2015
Tommaso Falcone, M.D.
Obstetrics and Gynecology; Lerner College of Medicine // Ob/Gyn & Womens Health Institute
Preserving the Fertility of Women with Cancer: Ovarian Tissue Freezing
Co-Investigator | Rebecca Flyckt, M.D.

PELIATRIC / YOUNG ADULT

PILOT | 2014
Charis Eng, M.D., Ph.D.
Genomic Medicine Institute; Lerner Research Institute
Exome Sequencing in Children, and Adolescents and Young Adult (AYA) Patients with Malignancies
Co-PI | Johannes Wolff, M.D.

PILOT | 2015
Violette Recinos, M.D.
Section Head, Pediatric Neurosurgical Oncology; Neurological Institute
Inhibition of Histone Methyltransferase with Novel Etipolythiodioxopiperazines (ETP) Alkaloids in Pediatric High Grade Glioma

IMPACT | 2016
Rabi Hanna, M.D.
Pediatric Hematology Oncology and Blood and Marrow Transplantation; Cleveland Clinic Children's Hospital
Quantification of Therapeutic Responses in Pediatric and AYA Hodgkin Lymphoma Patients via Detection of Circulating Tumor DNA

PROSTATE CANCER

IMPACT | 2014
Nima Sharifi, M.D.
Cancer Biology; Lerner Research Institute
Prostate Cancer

PILOT | 2016
Hannalore Heemers, Ph.D.
Department of Cancer Biology; Lerner Research Institute
Targeting the Interaction Between the Drivers of Lethal Cancer Progression as a Novel Treatment Strategy for Prostate Cancer

PILOT | 2016
Nima Sharifi, M.D.
Department of Cancer Biology, Lerner Research Institute; Department of Hematology and Oncology, Taussig Cancer Institute; Department of Urology, Glickman Urological and Kidney Institute
Determining the Role of Aberrant Glucocorticoid Metabolism in Enzalutamide-Resistant Prostate Cancer
Collaborators | Jorge Garcia, M.D., Department of Hematology and Oncology, Taussig Cancer Institute | Eric Klein, M.D., Department of Urology, Glickman Urological and Kidney Institute

PILOT | 2016
Jonathan D. Smith, Ph.D.
Dept. of Cellular & Molecular Medicine; Lerner Research Institute
Targeting HDL Metabolism to Prevent Progression to Lethal Prostate Cancer
Collaborator | Nima Sharifi, M.D., Dept. of Cancer Biology LRI and The Glickman Urological & Kidney Institute
Project Descriptions

**SKIN CANCER**

**IMPACT | 2014**

**Marc Ernstoff, M.D.**
Hematology and Oncology; Taussig Cancer Institute
Translational Melanoma

**GENERAL**

**PILOT | 2014**

**Claudia Marcela-Diaz, PhD**
Lerner Research Institute
Enhancing the Clinical Efficacy of Genetically Modified T Cells for Adoptive Cell Therapy

**PILOT | 2014**

**Candece L. Gladson, M.D.**
Cancer Biology; Lerner Research Institute
Endocytosis as a determinant of response to mAb therapy

**PILOT | 2014**

**Betty Hamilton, M.D.**
Hematology and Oncology; Taussig Cancer Institute
Enhancing the Suppressive Function of Inducible Regulatory T Cell Function with IL-27 to Prevent Graft-Versus-Host Disease

**PILOT | 2014**

**Navneet Majhail, M.D.**
Hematology and Oncology; Taussig Cancer Institute
Molecular High-Precision Monitoring of T-Cell Repertoire of Allogeneic Stem Cell Transplant

**PILOT | 2014**

**Frederic J. Reu, M.D.**
Hematology and Oncology; Taussig Cancer Institute
Development of a Novel Class of Anticancer Protein Disulfide Isomerase (PDI) Inhibitors

**PILOT | 2014**

**Qing Yi, M.D., Ph.D.**
Cancer Biology; Lerner Research Institute
Generating IL-9-Producing Tc9 Cells for Adoptive T Cell Therapies of Human Cancer
Co-PI | Young Lu, Ph.D., Research Fellow

**IMPACT | 2014**

**Dale Shepard, M.D., Ph.D.**
Hematology and Oncology; Taussig Cancer Institute
Phase 1 Clinical Trials

**PILOT | 2015**

**George Stark, Ph.D.**
Staff, Cancer Biology; Lerner Research Institute
New Strategies for the Preferential Killing of Cancer Stem Cells
Co-Investigator | Sarmishtha De, Project Staff, Cancer Biology Lerner Research Institute

**PILOT | 2015**

**Angela Ting, Ph.D.**
Assistant Staff, Genomic Medicine Institute
Understanding the Full Spectrum of Epigenetic Vulnerability in Cancer through the Delineation of DNA Methylation Function in Gene 3’ End

**IMPACT | 2015**

**Mohamed Abazeed, M.D.**
Radiation Oncology; Taussig Cancer Institute
Precision Targeting of Therapeutic Resistance in Cancer
Co-PI | Shlomo A. Koyfman, M.D., Radiation Oncology
## Project Descriptions

### PILOT | 2016
**Justin Lathia, Ph.D.**
Department of Cellular and Molecular Medicine; Lerner Research Institute

**Development of a Cancer Stem Cell Targeting Strategy via Disrupting Cell-Cell Communication**
Co-Investigators | James Phillips, Ph.D. | Babal Jha, Ph.D., Translational Hematology and Oncology Research Taussig Cancer Institute

### PILOT | 2016
**Michelle Longworth, Ph.D.**
Cellular and Molecular Medicine; Lerner Research Institute

**Genome Organizer-Mediated Repression of LINE-1 Retrotransposition during Inflammation**

### PILOT | 2016
**Keith McCrae, M.D.**
Department of Hematology and Solid Tumor Oncology; Taussig Cancer Institute

**High Molecular Weight Kininogen: A Novel Tumor Suppressor**

### PILOT | 2016
**James Phillips, Ph.D.**
Dept. of Translational Hematologic & Oncology Research; Taussig Cancer Institute

**Targeting the SET-SETBP1-PP2A Oncogenic Nexus by Small Molecules to Prevent Cancer Progenitor Cell Growth and Induce Terminal Differentiation and Death**
Co-Investigator | Babal Kant Jha, Ph.D., Dept. of Translational Hematologic & Oncology Research

### PILOT | 2016
**Frederic J. Reu, M.D.**
Department of Translational Hematology and Oncology Research; Taussig Cancer Institute

**An Intrabody Approach to Define the value of Protein Disulfide Isomerase (PDI) Inhibition in Oncology**
Co-Investigator | Babal Jha, Ph.D., Department of Translational Hematology and Oncology Research, Taussig Cancer Institute

### PILOT | 2016
**James Phillips, Ph.D.**
Dept. of Translational Hematologic & Oncology Research; Taussig Cancer Institute

**Targeting the SET-SETBP1-PP2A Oncogenic Nexus by Small Molecules to Prevent Cancer Progenitor Cell Growth and Induce Terminal Differentiation and Death**
Co-Investigator | Babal Kant Jha, Ph.D., Dept. of Translational Hematologic & Oncology Research

### PILOT | 2016
**Mark W. Jackson, Ph.D.**
Case Comprehensive Cancer Center

**A High-Throughput Screen for Inhibitors of Cancer Stem Cell Plasticity**
Co-PI | Drew Adams

### CCC | 2015
**Julian Kim, M.D.**
Case Comprehensive Cancer Center

**Development of Intravenously Injectable B-Glucan Treatment for Regulating Granulocytic Myeloid-Derived Suppressive Cells**

### CCC | 2015
**Huiping Lui, M.D., Ph.D.**
Case Comprehensive Cancer Center

**Identification of Surface Proteins Required for Internalization of Therapeutic Exomes**

### CCC | 2015
**Shigemi Matsuyama, DVM, Ph.D.**
Case Comprehensive Cancer Center

**Development of New Type of Therapeutics Selectively Targeting Bax or Bak**

### CCC | 2016
**Stanton Gerson, M.D.**
Case Comprehensive Cancer Center

**Inhibitors to the Human UNG by High-Throughput Small-Molecule Screening (HTS)**

### CCC | 2016
**Mark W. Jackson, Ph.D.**
Case Comprehensive Cancer Center

**A High-Throughput Screen for Inhibitors of Cancer Stem Cell Plasticity**
Co-PI | Drew Adams

### CCC | 2016
**Alvin Schmaier, M.D.**
Case Comprehensive Cancer Center

**Tyrosine Kinase Inhibitors and Cardiovascular Events in CML**

### IMPACT | 2015
**Alok Khorana, M.D.**
Hematology and Oncology; Taussig Cancer Institute

**Cancer Thrombosis**
Co-PI | Keith McCrae, M.D., Hematology and Oncology

### IMPACT | 2016
**Alok Khorana, M.D.**
Hematology and Oncology; Taussig Cancer Institute

**Cancer Thrombosis**
Co-PI | Keith McCrae, M.D., Hematology and Oncology